Corda Investment Management LLC. There is $29.03 million position in Johnson & Johnson (NYSE:JNJ)

Corda Investment Management LLC. cut its stake in shares of Johnson & Johnson (NYSE: JNJ – GET Rating) by 0.8% in the second quarter, HoldingsChannel.com reports. The firm held 163,533 shares of the company’s stock after selling 1,366 shares during the quarter. Johnson & Johnson holds 2.5% of Corda Investment Management LLC’s investment portfolio, making the stock its 19th largest position. At the end of the most recent quarter, Corda Investment Management LLC’s holding in Johnson & Johnson was worth $29,028,000.

Other large investors have also bought and sold shares of the company recently. RE Dickinson Investment Advisors LLC increased its holding in Johnson & Johnson shares to 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company valued at $28,000 after buying an additional 98 shares during the period. Advanced Research Investment Solutions LLC boosted its stake in shares of Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after buying an additional 120 shares during the period. Morton Brown Family Wealth LLC increased its holding in shares of Johnson & Johnson to 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company worth $32,000 after buying an additional 78 shares during the period. Professional Financial Advisors LLC increased its holding in Johnson & Johnson shares to 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after purchasing an additional 68 shares during the period. Finally, Goodman Advisory Group LLC purchased a new position in Johnson & Johnson during the second quarter worth $39,000. 68.59% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson stock up 0.8%

Shares of JNJ opened on Monday at $176.20. The company has a market capitalization of $460.67 billion, a PE ratio of 24.54, a PEG ratio of 3.49, and a beta of 0.57. Johnson & Johnson’s 12-month low is $155.72 and its 12-month high is $186.69. The stock’s 50-day moving average price is $167.84, and its two-hundred-day moving average price is $171.29. The company has a current ratio of 1.43, quick ratio of 1.18 and debt-to-equity ratio of 0.37.

Want more great investment ideas?

Johnson & Johnson (NYSE: JNJ – GET Rating) last announced its earnings results on Tuesday, October 18. The company reported EPS of $2.55 for the quarter, a $0.06 increase over the consensus estimate of $2.49. The firm had revenue of $23.79 billion for the quarter, compared to consensus estimates of $23.44 billion. Johnson & Johnson’s return on equity was 35.37% and net margin was 19.95%. The business’s quarterly revenue was up 1.9% over the same quarter last year. During the same period last year, the business earned $2.60 EPS. On average, analysts expect Johnson & Johnson to post 10.04 EPS for the current year.

Johnson & Johnson declares dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. A dividend of $1.13 will be paid to stockholders of record on Tuesday, November 22nd. This represents a $4.52 annual dividend and a dividend yield of 2.57%. The ex-dividend date for this dividend is Monday, November 21. The Dividend Payout Ratio (DPR) of Johnson & Johnson currently stands at 62.95%.

Johnson & Johnson announced that its board of directors has approved a share repurchase program on Wednesday, September 14 that authorizes the company to buy back $5.00 billion of shares. This buyback authorization authorizes the company to buy back up to 1.2% of its shares through open market purchases. A share buyback program is often a sign that a company’s board believes its stock is not undervalued.

Wall Street analysts forecast growth

JNJ has been the subject of several recent research reports. Morgan Stanley cut their price objective on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19. Barclays initiated coverage on Johnson & Johnson in a report on Monday, October 17. He issued an “equal weight” rating and a target price of $175.00 on the stock. Bank of America lowered its target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14. Raymond James cut his price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19. Finally, StockNews.com began coverage on Johnson & Johnson in a report on Wednesday, October 12. He has set a “strong-buy” rating on the stock. Seven analysts have hold ratings on the stock, four have buy ratings and one has strong buy ratings on the stock. Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33, according to data from MarketBeat.com.

Insider Trading at Johnson & Johnson

In other news, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction on Wednesday, October 19. The stock was sold at an average price of $164.50 for a total value of $3,761,128.00. Following the completion of the transaction, the Vice President now directly owns 114,676 shares of Company stock, valued at approximately $18,864,202. The transaction was disclosed in a filing with the SEC, which can be accessed via this hyperlink. In related news, insider William Hatt sold 15,000 shares of the business’s stock in a single transaction on Monday, October 24. The stock was sold at an average price of $171.55 for a total value of $2,573,250.00. Following completion of the sale, the insider now directly owns 80,236 shares of Company stock, valued at approximately $13,764,485.80. The sale was disclosed in a filing with the Securities and Exchange Commission, which can be accessed via this link. Additionally, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction that occurred on Wednesday, October 19. The stock was sold at an average price of $164.50 for a total value of $3,761,128.00. Following the sale, the vice president now directly owns 114,676 shares of the company’s stock, valued at $18,864,202. Disclosure of this sale can be found here. Over the past ninety days, insiders sold 118,795 shares of the company’s stock, valued at $20,230,174. Corporate insiders own 0.35% of the company’s stock.

About Johnson & Johnson

(get rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells a variety of products in the healthcare sector around the world. The company’s Consumer Health segment offers baby care products under the Johnson’s and Aveeno Baby brands; oral care products under the Listerine brand; Skin health/beauty products under AVEENO, Clean & Clear, DR.

Featured Articles

Want to see what other hedge funds are in JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Ratings ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE: JNJ)

Receive news and ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.

Then We Knew It Was on..” – Roman Reigns Shark Tank Keto Gummies Scam Alert? McDonald’s Halloween Buckets Could Be Back How to Watch Spacecraft Collide With Deep Space Asteroid Grand Theft Auto VI footage leaked after the hack Floyd Mayweather Jr boxer knocks out Mikuru Asakura martial artist